Ocular and eyelid involvement in collagen vascular diseases. Part I. Sjögren syndrome and systemic lupus erythematosus.

Collagen vascular disease is a heterogeneous group of autoimmune diseases that affect multiple organ systems. Sjögren syndrome, dermatomyositis, scleroderma, systemic lupus erythematosus, and sarcoidosis are collagen vascular diseases that often present with characteristic cutaneous manifestations. Although less known, various ocular manifestations that affect both external and internal structures of the eye can be seen in these conditions. Multidisciplinary management between dermatologists and ophthalmologists is essential in the early diagnosis and management of collagen vascular diseases affecting both the skin and eye. Part I of our series will discuss the ocular manifestations, their diagnosis, and therapeutic options in Sjögren syndrome and systemic lupus erythematosus.

Ocular and eyelid involvement in collagen vascular diseases. Part II. Dermatomyositis, scleroderma, and sarcoidosis.

Collagen vascular disease is a heterogeneous group of autoimmune diseases that affect multiple organ systems. Sjögren syndrome, dermatomyositis, scleroderma, systemic lupus erythematosus, and sarcoidosis are collagen vascular diseases that often present with characteristic cutaneous manifestations. Although less known, various ocular manifestations that affect both external and internal structures of the eye can also be seen in these conditions. Multidisciplinary management between dermatologists and ophthalmologists is essential in the early diagnosis and management of collagen vascular diseases affecting both the skin and eye. In part II of our series, we discuss the ocular manifestations, diagnosis, and therapeutic options of dermatomyositis, scleroderma, and sarcoidosis.

Targeting dysbiosis in psoriasis, atopic dermatitis, and hidradenitis suppurativa: the gut-skin axis and microbiome-directed therapy.

Emerging evidence highlights the gut-skin microbiota as a potential therapeutic target for the management of inflammatory-driven cutaneous diseases as well as the interconnection of the gut-skin microbiota in disease pathogenesis and progression. Although not fully understood, recent research has indicated that commensal microbiota and the interaction of the gut-skin axis play an important role in maintaining skin homeostasis. Dysbiosis and disruption of the skin-gut microbiome may lead to impaired skin barrier function, thus triggering downstream inflammatory responses involved in the development of inflammatory skin disorders, especially in atopic dermatitis, psoriasis, and hidradenitis suppurativa. The skin microbiome may also serve as adjunctive therapeutic modalities for treatment. Herein, we review the latest reports on the interrelationship between microbial dysbiosis and inflammatory cutaneous diseases as well as emerging microbiome-directed therapeutics in atopic dermatitis, psoriasis, and hidradenitis suppurativa.

Routine eyelid care for those without dermatitis.

The eye is a unique structural and functional anatomic unit of the face and requires specific care and attention. Often, dermatologists are not familiar with the routine needs of the eyelid area. Despite evidence showing that lid hygiene may serve as an important supplement to therapeutic management of eyelid disorders, lid hygiene is often overlooked. Ophthalmologists and dermatologists have an important role to play in educating patients on the importance of proper eyelid hygiene and ensuring patient compliance. We review eyelid anatomy and function to better understand how these structures relate to potential disease processes. We also review current recommendations for routine eyelid care and discuss the need for further advancements in promoting eyelid health.

Modified Fitzpatrick Scale-Skin Color and Reactivity.

BACKGROUND: There is growing interest in the development of a skin classification system that captures the world's diverse population. The Fitzpatrick skin classification scale is used both clinically and in research settings to determine an individual's skin color. With the high global burden of skin sensitivity (atopic dermatitis, keloid formation, etc), there is a need for a skin classification system that takes into consideration an individual's reaction to environmental insults and injuries. Our proposal builds on the existing Fitzpatrick skin classification scale by asking two additional questions of patients: do patients have sensitive skin; do patients have a history of hypertrophic scarring or keloids. By separating patients into 2 categories (sensitive vs non-sensitive skin), we create a system that can help dermatologists decide on which treatments to offer patients based on their skin classification. Dermatologists can better predict patient outcomes for dermatologic or cosmetic procedures by knowing how they react to environmental insults/injury. Santiago S, Brown R, Shao K, et al. Modified fitzpatrick scale- skin color and reactivity. J Drugs Dermatol. 2023;22(7):641-646. doi:10.36849/JDD.6859.  .

Atypical Wells syndrome successfully treated with dupilumab.

Wells syndrome, also referred to as eosinophilic cellulitis, is a rare and often sporadic inflammatory skin condition whose aetiology remains uncertain. Clinically, this condition presents as a collection of erythematous, oedematous, and tender skin lesions most often affecting the extremities and trunk that can mimic cellulitis. Histologically, Wells syndrome is characterised by inflammatory changes and eosinophilic infiltration of the dermis with the absence of underlying infection, thereby distinguishing it from cellulitis. Due to the rarity of this syndrome and its ambiguous presentation, there remains to be a definitive strategy for treatment. Recent case reports have documented varying success and recurrence with the use of oral and topical corticosteroids, antifungals, antibiotics, immunosuppressants and antihistamines. Here, we report a unique case of progressively worsening neutrophilic-rich Wells syndrome on the vertex of the scalp that was successfully treated with a combination of dupilumab and oral corticosteroids.

Patient Satisfaction in Teledermatology: an Updated Review.

Purpose of Review: Teledermatology continues to gain popularity across the world. It is crucial that dermatologists understand patient experience and satisfaction to effectively incorporate this practice into patient care. This article provides an updated review of recent findings on patient satisfaction in teledermatology. Recent Findings: Over the last 2 years, there has been an increase in studies on the patient experience of live-video teledermatology, while previous studies largely focused on store-and-forward teledermatology. This reflects the expansion of live-video teledermatology since the COVID-19 pandemic. Patients are generally very satisfied with both store-and-forward and live-video teledermatology, valuing its accessibility, quality of care, and patient-provider relationship. Decreased patient satisfaction is linked to technical difficulties, privacy concerns, lack of procedure availability, and thorough physical exams. However, teledermatology experiences are not equal across demographic groups. Access to technical support, digital literacy, age, social economic status, and type of dermatological conditions have all been found to affect patient experience. Summary: Studies show high levels of patient satisfaction in teledermatology but limitations exist. Future efforts to improve teledermatology experiences will require reducing barriers among demographics, improving patient education, investment in technology, and collaboration among all parties involved.

Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sjögren syndrome.

The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The first article in this continuing medical education series discusses new and emerging therapeutics for lupus erythematosus and Sjögren syndrome that target cells, intracellular signaling pathways, and cytokines.

Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma.

The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The second article in this continuing medical education series discusses new and emerging therapeutics for dermatomyositis and scleroderma that target cells, intracellular signaling pathways, and cytokines.